Our PSEL-MZL exhibited a MYD88 L265P mutation, known to constitutively activate NF-κB signaling and associated with extranodal disease and inferior outcomes in various B cell lymphomas [14]. Here, MYD88 is linked to B-cell non-Hodgkin lymphoma.